Molecular pathways of urothelial development and bladder tumorigenesis (Q37770779)

22 August 2017

1 reference

title

Molecular pathways of urothelial development and bladder tumorigenesis (English)

1 reference

22 August 2017

5

Carlos Cordon-Cardo

1 reference

22 August 2017

3

Orit Karni-Schmidt

1 reference

PubMed ID

20610278

22 August 2017

Mireia Castillo-Martin

series ordinal

1

object named as

Mireia Castillo-Martin

1 reference

22 August 2017

Josep Domingo-Domenech

series ordinal

2

1 reference

PubMed ID

20610278

22 August 2017

Tulio Matos

series ordinal

4

1 reference

22 August 2017

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

28

1 reference

22 August 2017

401-408

1 reference

22 August 2017

4

1 reference

22 August 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

The pathology of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

7 January 2021

Focus on bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

'Superficial' bladder cancer - time to uncouple pT1 tumours from pTa tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Molecular alterations associated with bladder cancer initiation and progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

More than one way to skin . .

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

The human keratins: biology and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Cytokeratin 20 as an objective marker of urothelial dysplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Expression of blood group antigens in bladder cancer: current concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

"Cancer stem cells"-lessons from Hercules to fight the Hydra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Identification and characterization of adult stem/progenitor cells in the human bladder (bladder spheroids): perspectives of application in pediatric surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Urothelial progenitor cells: regional differences in the rat bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Loss of p63 expression is associated with tumor progression in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Targeted therapies in bladder cancer--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Genetic alterations in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Mutation of the 9q34 gene TSC1 in sporadic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

PTCH gene mutations in invasive transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

DBC1 re-expression alters the expression of multiple components of the plasminogen pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

p53 mutations in human bladder cancer: genotypic versus phenotypic patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

The multiple roles of PTEN in tumor suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Inactivation of p53 and Pten promotes invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.04.019

10.1016/J.UROLONC.2009.04.019

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20610278